The FDA has approved Idorsia's daily drug TRYVIO (aprocitentan), the first to use an endothelin receptor antagonist for managing resistant hypertension alongside other medications.

Mabwell's novel antibody-drug conjugate targeting Nectin-4 in cervical cancer shows significant treatment promise according to initial clinical findings.

Dr. Reddy’s Laboratories Ltd., an international enterprise specializing in pharmaceuticals, has officially declared the introduction of its drug Versavo® (bevacizumab) to the UK market.

Orchard Therapeutics has obtained U.S. FDA endorsement for Lenmeldy™, a proprietary treatment branded as atidarsagene autotemcel, designed exclusively for young patients diagnosed with early-stage Metachromatic Leukodystrophy.

The deal encompasses a clinical-phase actinium radioconjugate aimed at PSMA to combat prostate cancer, a collection of radioconjugate products in development, and cutting-edge research, development, and production infrastructure.

Lynparza and Imfinzi substantially increased the average response time, outperforming chemotherapy, in providing clinical advantages for individuals with advanced or relapsed endometrial cancer that shows proficient DNA mismatch repair.

Intellia Therapeutics has revealed the initiation of their Phase 3 clinical trial named MAGNITUDE, where the first participant received a one-time CRISPR therapy, NTLA-2001, aimed at treating cardiac amyloidosis caused by transthyretin.

During the 2024 ACS Spring Meeting, Brenig Therapeutics showcased novel findings related to their leading LRRK2 inhibitor, which is aimed at tackling Parkinson's disease.

Citius Pharmaceuticals Reveals the U.S. FDA's Approval of a Revised BLA for LYMPHIR™ (Denileukin Diftitox), Aimed at Treating Reoccuring or Treatment-Resistant Cutaneous T-Cell Lymphoma in Adults.

Shanghai Henlius Biotech, Inc. has reported the commencement of a phase 1 clinical study for HLX42, by administering the initial dose to a participant.

Formycon and Fresenius Kabi have concluded a resolution for their biosimilar contender FYB202, based on ustekinumab, targeting markets in Europe and Canada.

KeChow Pharma announces that its drug Tunlametinib (HL-085) has been approved by the NMPA, becoming the first targeted therapy approved for the treatment of NRAS-mutant advanced melanoma patients who have been previously treated with PD-1/PD-L1 therapy.